James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED).
The study will recruit approximately 1,000 patients with mild, moderate and severe ED and compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2002 against that of the placebo.
Meet Peninsula Mines Ltd and Silver City Minerals Ltd at our event,Sydney, 07 May 2018.Register here >>